Investors Cut Tech Allocations at Fastest Pace Since 2006 on Data Center Spending Concerns
Published 6 h ago2 sourcesEvidence: Reported
The biotech sector is experiencing a rebound in 2026, but investor response to positive clinical data has been muted and selective, indicating a divergence between overall sector performance and individual stock reactions. This suggests investors are prioritizing commercial viability and risk over scientific milestones, potentially signaling a more cautious capital allocation environment for biotech.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 6 h ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 1 d ago10 sourcesEvidence: Reported
Published 1 d ago7 sourcesEvidence: Unknown
Published 1 d ago4 sourcesEvidence: Reported
Published 21 h ago4 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported